TAKEDA PHARMACEUTICALS AMERICA, INC. lobbying for TAKEDA PHARMACEUTICALS AMERICA INC

Filing 2nd Quarter - Report

Reporting period

2nd Quarter 2026

Apr 1 - June 30 · Posted Jul 20, 2026

Expenses

$610,000.00

What this organization spent lobbying with its own staff. Reported using A: the three LDA methods count different costs, so an expenses figure is not comparable across filers that used different ones.

Client based in

District of Columbia

Official filing document

Government bodies contacted 5

HOUSE OF REPRESENTATIVES
Office of Management & Budget (OMB)
SENATE
U.S. International Trade Commission (ITC)
U.S. Trade Representative (USTR)

The chambers, agencies and offices the filer named. It does not say who inside them was contacted, or when.

Bills named in this filing 4

HR 1
An act to provide for reconciliation pursuant to title II of H. Con. Res. 14.
S 832
EPIC Act of 2025
HR 946
ORPHAN Cures Act
HR 4229
To amend the Impoundment Control Act of 1974 to require prior approval from Congress before the Comptroller General may…

Lobbying activity 5

Budget/Appropriations

FY 2025 Budget Resolution - Pharmaceutical Related Provisions

Medicare/Medicaid

Policies to enhance patient access to medicines in Medicaid including rebate, waiver policy and funding issues Policies to enhance patient access to medicines in Medicare Review of proposed rule regarding testing of Medicare part B prescription drug models Medicare payment proposals Request for Regulatory Clarification with Medicare Part B Group (CMS) Medicare Drug Price Negotiation Program: Selected Drugs for Initial Price Applicability Year 2026 Request for Regulatory Clarification with Medicare Administrative Contractor (CMS) Discussions on spillover related to the IRA Medicare Drug Price Negotiation Program: Selected Drugs for Initial Price Applicability Year 2027 Medicare Drug Price Negotiation Program: Selected Drugs for Initial Price Applicability Year 2028 Discussions on reforming the Inflation Reduction Act Discussions on orphan drugs related to the IRA Discussions on treatment of small molecule drugs related to IRA H.R.1 492, S. 832, EPIC Act of 2025 H.R. 946, Optimizing Research Progress Hope and New (ORPHAN) Cures Act HR 4229 Protecting Patient Access to Cancer & Complex Therapies Act

Health Issues

Clarify or reform the 340B program Value-based drug contracting Patient access of plasma therapies Global pharmaceutical supply chain operations and manufacturing locations Most Favored Nation/International Reference Pricing Co-pay accumulators maximizers, alternate funding models Promoting the Congressional Plasma Caucus Rare disease diagnosis and access to care Senate Finance Committee PBM Framework Paper Pharmacy Benefit Managers (PBMs) Drug pricing, including House and Senate draft bills Bayh-Dole march-in rights policy issues SECURE 340B Act (bill# not listed yet) Senate Finance Committee Drug Pricing RFI

Trade (domestic/foreign)

Issues related to proposed Tariffs - all pharmaceutical related provisions

Defense

Discussions around Supply Chain implications BIOSECURE implementation COINS implementation